Application of novel oral anticoagulants for the antithrombotic effect of cardiovascular system diseases

  • Runtian Xiao Shaoxing University Yuanpei College
Keywords: Warfarin; Novel Oral Anticoagulants; Anticoagulant Therapy; Cardiovascular Disease


Long-term oral anticoagulant is one of the methods for the treatment of cardiovascular system diseases, and the most widely used anticoagulant drug is warfarin, but its clinical application has been greatly limited due to its slow onset, easy to affect by various factors, and difficult dose control. In recent years, with the continuous in-depth research on cardiovascular system diseases, the emergence of new oral anticoagulants (NOAC) has greatly impacted the status of traditional anticoagulant warfarin because of its safety, stability and convenience of consumption. The purpose of this article is to review the classification and application of novel oral anticoagulants.


[1] Thomas, Wilke, Antje, et al. Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large

sample of 38,076 German patients.[J]. European Journal of Clinical Pharmacology, 2017.

[2] Simone, Stehle, Julia, et al. Pharmacogenetics of Oral Anticoagulants[J]. Clinical Pharmacokinetics, 2008.

[3] Chatterjee S , Sharma A , Uchino K , et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial

sequential analysis of randomized clinical trials.[J]. Coron Artery Dis, 2013, 24(8).

[4] Brinkmeier-Theofanopoulou M , Tzamalis P , Wehrkamp-Richter S , et al. Periprocedural anticoagulation during left atrial ab_x005flation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants[J]. Bmc Cardiovascular Disorders, 2018,


[5] Stangier D J , Hildegard Sthle, Rathgen D K , et al. Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment[J]. The Journal of Clinical Pharmacology, 2008.

[6] Samama M M . The mechanism of action of rivaroxaban - An oral, direct Factor Xa inhibitor - Compared with other anticoagulants[J]. Thrombosis Research, 2010, 127(6):497-504.

[7] Reinhold, Kreutz. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.[J]. Current Clinical

Pharmacology, 2014.

[8] Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor[J]. Current clinical pharmacology, 2014, 9(1): 75-83.

[9] Zhenxia, Zhang, Wang Jing The therapeutic effect of rivaroxaban on atrial fibrillation [J] Clinical Medical Research and Practice,

2018, 3 (32): 2

[10] Donglu, Zhang, Charles, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of

activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.[J]. Drug metabolism and disposition: the biological fate of chemicals, 2013.

[11] Bounameaux H , Camm A J . Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor[J]. Drugs, 2014, 74(12):1455-


[12] Raskob G , Cohen A , Eriksson B , et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement[J]. Thromb Haemost, 2010, 104(09):642-649.

[13] Huisman, M. V , Lip, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties

in routine practice[J]. Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis, 2012, 107(5):838-


Review Article